Interchangeable Biosimilars: Key Points for Patients

undefined

SPEAKER
Jonathan Kay picture

Jonathan Kay, MD
UMass Memorial Health
Worcester, MA

Part 1
Defining Interchangeable
Biologics and Their ValuePart 2
Achieving Interchangeability
StatusPart 3
Extrapolating Indications

Jonathan Kay, MD, defines biosimilarity and the necessary requirements for that designation and discusses the implications of interchangeability on patient access to biological products.

©2022 Boehringer Ingelheim Inc. All Rights Reserved. SC-US-74798 11/22